Pharmedica USA Purely Soothing 15% MSM eye drops recalled due to non-sterility

Article

Contaminated Purely Soothing 15% MSM drops carry risk of eye infections that may result in vision loss. All consumers should stop use immediately.

Pharmedica USA LLC has voluntarily recalled two lots of Purely Soothing 15% MSM eye drops due to non-sterility at the consumer level. No adverse events or illness have been reported at the time of recall, but the FDA urges consumers to stop use of the drops and return bottles to the place of purchase. Retailers and wholesalers should immediately pause distribution and return stock to Pharmedica USA or verify proper disposal with the FDA.

Patients who experience irritation or signs of infection following use should immediately talk to their eye care provider. Optometrists should advise patients against use. Purely Soothing 15% MSM eye drops were distributed worldwide via e-commerce, so advise patients to check any drops they have purchased online.

The Purely Soothing 15% MSM eye drops are an anti-inflammatory topical solution that soothe ocular irritation and swelling. The white, cylindrical HDPE bottles are capped with droppers and white lids.

These drops can be identified by their LOT numbers (LOT#: 2203PS01, 1 oz, UPC 7 31034 91379 9; and LOT#: 1808051, ½ oz, UPC 7 31034 91382 9) and have eye dropper caps and white lids.

Consumers with questions regarding the recall can contact Pharmedica USA LLC via phone at 1-623-698-1752 or email at osm@pharmedicausa.com Monday through Friday between 8 am and 5 pm MST. Those experiencing any problems that may be related to the drug product should contact their physician or healthcare provider.

Consumers experiencing adverse reactions of quality problems after use of these eye drops may report to the FDA’s MedWatch Adverse Event Reporting program online, by mail, or by fax.

  • Report the problem online
  • Download the form to mail a report in, or call 1-800-FDA-0178 to request a form to complete and return to the address on the pre-addressed form, or submit it by fax to 1-800-FDA-0178
Recent Videos
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
Bonnie An Henderson in an interview for the EnVision Summit
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
© 2025 MJH Life Sciences

All rights reserved.